What Is Triple Negative Breast Cancer
Triple Negative Breast Cancer
‘ Triple negative ‘ is a terminology/term used to describe one of the several types of breast cancer. The meaning of ‘ triple negative ‘ is if the type of breast cancer who DO NOT HAVE suffered in one of three receptor/receiver which is normally found on the surface of breast cancer cells. Receptors are receptors that do not exist are: estrogen receptors, progesterone receptors and Her2 receptor.
Around 15%-25% of cases of breast cancer are found of type ‘ triple negative ‘. Chemotherapy usually become the first choice of treatment against breast cancer is of type ‘ triple negative ‘.
Therapy of breast cancer with ‘ triple negative ‘ usually involves surgery/surgery (lumpectomy or mastectomy), followed by radiotherapy if a lumpectomy is done, and coupled with chemotherapy.
Treatment with chemotherapy found particularly suitable for breast cancer type ‘ triple negative ‘. Observations of the experts ‘ level indicates the level of survival (survival without or with symptoms) of patients with breast cancer is of type ‘ triple negative ‘ higher in the next period after undergoing a series of such treatment.
Cancer expert physician (medical oncology specialist) who are caring for you will be putting together a ‘ plan of therapy with chemotherapy ‘, taking into account all the circumstances of the special/individual yourself.
Although chemotherapy is usually given after surgery, sometimes also given chemotherapy before surgery. Chemotherapy given before surgery is usually done when the tumor size is categorized sufficiently large and there is an inherent part of the tumor or too near denngan organs, such as the chest muscles. The goal of chemotherapy before surgery is to minimize the size of the tumor before the action is performed. This will facilitate the Oncology surgeon take tumors and all parts of the tumor that possibility can easy left and attached to organs near the tumor. Chemotherapy given in this way is called ‘ neo-adjuvants chemotherapy ‘. (see the section on chemotherapy in this blog).
The difference in breast cancer type ‘ triple negative ‘ breast cancer type to another.
If you’re in diagnosis with breast cancer type ‘ triple negative ‘, as already explained in the above definition, it means that your breast cancer cells do not have one or all of the three types of receptors that are normally found on the surface of breast cancer cells.
Three receptors that are normally found on the surface of breast cancer cells are as follows:
Oestrogen (Estrogen) receptors (ER)
Progesterone (Progesterone) receptors (PR)
Human Epidermal Growth Factor Receptor 2 (HER2)
If you compare your therapy (as a patient with triple negative breast cancer type) with fellow breast cancer patients with another type, it is likely that you receive different therapies with their generally with other types of breast cancer.
In those with breast cancer with estrogen and/or progresteron receptor positive (ER +), will usually be teraphy with tamoxifen or an aromatase inhibitor class of drugs (e.g., Femara and Arimidex) as one part of the whole therapy is accepted.
Women with breast cancer that is HER2 receptor positive (HER2 +), will usually be given the drug Herceptin.
These drugs (Tamoxifen, Aromatase inhibitors and Herceptine) known as ‘ targeted therapies ‘, where these drugs will not be effective to treat breast cancer with type ‘ triple negative ‘.
What at the time was called ‘ targeted therapy ‘ (meaning roughly therapy that clearly target a goal – in this case the presence of receptors then obviously where the street expected therapy works well to avoid breast cancer grow back) is not yet available for women with breast cancer type ‘ triple negative ‘. But at the moment, an awful lot of research is being done in order to find targeted ‘ therapy ‘ for triple negative ‘ breast cancer ‘.
Below is a list of some of the research/research is currently being conducted in an attempt to find the ‘ targeted therapy ‘ on triple negative ‘ breast cancer ‘.